NOVEL STEM CELL EXPANSION TECHNOLOGY
UNMODIFIED IMMUNE EFFECTOR CELL PROGRAM
Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP), together with its subsidiaries (including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., (collectively “Coeptis”), is a clinical stage biotechnology company developing innovative cell therapy platforms for patients with cancer and other debilitating diseases. Coeptis was founded in 2017 and is headquartered in Wexford, PA.
Management has demonstrated a track record of acquiring and developing novel therapies.
Chairman, President and Chief Executive Officer
Mr. Mehalick is a successful executive with a career spanning over 30 years across a variety of industries including life sciences, technology, financial services, military contracting, entertainment, and consumer products.
Mr. Mehalick’s career has allowed him deep immersion into all facets of executive management notably mergers and acquisitions, corporate finance, C- Suite management, product development and licensing, partnerships, product commercialization, and corporate communications.
He has assisted and managed several organizations towards successful investor monetization across all aspects of company evolution resulting in billions of dollars in transactions and financings. Currently, Mr. Mehalick is our Chairman, Chief Executive Officer and President, and one of our co-founders. He has been involved in several companies in a variety of positions and functions prior to Coeptis spanning many different industries.
Mr. Mehalick began his career in the financial services industry in the wealth management area before transitioning to investment banking in the early 2000’s. He held positions of Vice President and Senior Vice President at multiple firms notably First Union Capital Markets, Gruntal and Co. and Ferris Baker Watts. He then began working earnestly with companies to assist them in all aspects of growth.
He was a founding partner in American Defense Systems, a military contractor designing lightweight antiballistic armor and hardening systems for transportation and solid structures. After procuring several military contracts, the company grew revenues to a point that they became public on the AMEX stock exchange.
Throughout his career Mr. Mehalick was involved in numerous similar situations either in a management or consultant role to allow strong returns for shareholders via acquisitions or public strategies.
Chief Financial Officer
Brian Cogley is a senior-level financial executive with over 15 years of experience in corporate finance and accounting across a variety of industries, including life sciences, pharmaceuticals, financial services, and manufacturing.
Prior to joining Coeptis Therapeutics, Mr. Cogley was a Senior Manager in the Accounting Advisory practice at CFGI, LLC., where he served pharmaceutical and financial services clients in technical accounting implementations and execution. In this role, he led financial operations for client companies and successfully executed various financial projects while performing multiple interim management roles.
Formerly, Mr. Cogley worked as the Vice President of Finance & Accounting at NexTier Bank, after holding previous roles as Global Cash Manager, Senior Accountant, Financial Analyst and Senior Audit Associate across the finance industry, including at KPMG, a “Big 4” accounting firm.
In Mr. Cogley’s varied career experience, he developed expertise in financial planning, reporting and variance analysis, as well as in asset and liability management, handling cash, investments, derivatives and debt portfolios for efficient use of company funds.
A forward-thinker with problem-solving skills and enthusiasm, Mr. Cogley’s leadership of teams has resulted in innovative thinking and tangible results.
Mr. Cogley holds a bachelor’s degree in accounting and a Master of Business Administration with a concentration in finance from Duquesne University.
Chief Scientific and Medical Officer
Colleen Delaney, M.D., M.Sc., is a trained oncologist and stem cell transplant physician scientist. A highly accomplished and greatly respected leader, Dr. Delaney is pioneering methods to make umbilical cord blood transplants more available and successful worldwide.
Dr. Delaney brings more than two decades of experience to Coeptis. As a trained oncologist and stem cell transplant physician scientist with expertise in the translation of scientific discovery to clinical practice, she is proficient in all aspects of cell therapy product development, from initial discovery to pre-clinical and Investigational New Drug (IND)-enabling studies, manufacturing, global regulatory experience, and clinical trial design. She has served on federal advisory committees focused on multiple cell and gene therapy and acted as a director for several nonprofit associations.
In addition to her industry experience, Dr. Delaney is a clinical professor at the University of Washington, Division of Pediatric Hematology/Oncology, and is an affiliate and former professor at the Fred Hutch Cancer Center, where she also held the Madeline Dabney Adams Endowed Chair in Acute Myeloid Leukemia research. She earned her M.Sc. from Oxford University and her M.D. from Harvard Medical School.
VP of Compliance and Corporate Secretary
Christine Sheehy is a pharmaceutical business leader with over 25 years of experience, including globally commercializing drug products and working in development of targeted therapeutics including cell and gene therapies.
Ms. Sheehy was Senior Vice-President of Operations for Kadmon Pharmaceuticals, leading the global supply chain, distribution, and IT organizations. She was a founding employee of start-up pharmaceutical company Three Rivers Pharmaceuticals, which was acquired by Kadmon Pharmaceuticals in 2010. During that time, she launched branded and generic products in the U.S., leading the operational business.
Globally, Ms. Sheehy has executed international supply and distribution partnerships in Europe and Asia. Prior to Three Rivers Pharmaceuticals, Ms. Sheehy held various roles ranging from business and finance consulting to financial management.
Strategically minded, with a strong ability to understand all aspects of the business, her leadership skills have been developed by working substantially in start-ups and early-stage companies.
Additionally, over the past 15 years Ms. Sheehy has held board of director and advisory positions for multiple industry organizations, and she holds a bachelor’s degree in accounting from Penn State University.
Director and Vice President of Operations
Dan Yerace is a co-founder of Coeptis Pharmaceuticals and serves as the Vice President of Operations. Mr. Yerace has over ten years of experience in the pharmaceutical industry and is a key strategist responsible for supply chain management, business development, portfolio management, and corporate strategy.
Mr. Yerace has broad operational experience and has held leadership positions in procurement, global supply chain management, operations, and business development for small private firms and fortune 500 multi-national corporations.
Prior to joining Coeptis, Mr. Yerace served as Senior Director of Global Supply Chain and Commercial Business Development for Kadmon Pharmaceuticals.
Mr. Yerace holds a bachelor’s degree in economics, and a masters of business administration from Waynesburg University.
Our Scientific Advisory Board is comprised of leading scientists in cell and gene therapy.
Dr. Alici is the Head of the Gene and Cell Therapy Group, Division of Hematology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital.
As a senior researcher and group leader in Hematology at KI, Department of Medicine, he also serves as co-director of NextGenNK, an international Competence Center for the development of next-generation NK cell-based cancer immunotherapies based at KI. Dr. Alici received his M.D. and did his residency at the Ege University, Turkey. He earned his Ph.D. in 2006 at KI.
Dr. Alici’s main research interests are novel approaches to generating universal cells including allogeneic NK cells, multiple myeloma, lentiviral and retroviral gene transfer, stem cell transplantation and immunology.
Dr. Alici participated in the planning and design of the first clinical study with gene-modified cells in Sweden and authored the final publication. Additionally, he was also responsible for the first-in-man autologous NK cell therapy clinical trial that was classified as advanced therapy medicinal product use. Dr. Alici is affiliated with VyGen-Bio.
Professor Ljunggren is the former Dean of Research at Karolinska Institutet and founder of the Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital and has functioned as Dean of Research at KI. He is a member of the Nobel Assembly at KI, which awards the Nobel Prize in Physiology or Medicine.
Professor Ljunggren earned his medical and doctoral degrees at KI and also serves as Center Director of NextGenNK, an international Competence Center for the development of next-generation NK cell-based cancer immunotherapies based at KI. In 2001, he was appointed Professor of Infection Medicine and Director of the Center for Infectious Medicine (CIM), a Strategic Research Center at the Department of Medicine, and has authored over 300 articles within the fields of immunology, infectious diseases and cancer and been cited more than 40,000 times.
Professor Ljunggren has been a member of the organizing or scientific committees of numerous international conferences and has had multiple national and international assignments, involving external research evaluations and participation in international advisory boards. Dr. Ljunggren is affiliated with VyGen-Bio.
Since 2019, Dr. Wagner has been an assistant professor at the KI’s Dept. of Medicine Huddinge, studying NK cells in immunotherapy in Multiple Myeloma.
Dr. Wagner is particularly interested in advancing the use of genetically modified NK cells in different immunotherapeutic approaches.
Dr. Wagner earned her M.Sc. in 2008 from the University of Lübeck, Germany and conducted her Ph.D. studies under the supervision of Klas Kärre at the Dept of Microbiology, Tumor and Cell Biology, at KI, where her research focused on NK cells in mouse models for immunotherapy and studied the crosstalk of NK cells with other immune cells. Dr. Wagner is affiliated with VyGen-Bio.
Chief Financial Officer and President, Crown Global
Chris Calise, the Chief Financial Officer, and President, is responsible for setting the strategic vision for Crown Global as well as overseeing its day- to-day management, including finance, operations, and sales. He also works closely with both internal and external sales and marketing in the development of new product initiatives, as well as evaluating new markets.
Prior to joining Crown Global, Calise was a principal at LSC Investors, LLC, which advised The Second City, Inc. and Narciso Rodriguez and restructured Phillips de Pury & Luxembourg, the world’s third largest auction house. Prior to LSC, he was an associate with Crown Capital Group, Inc.; a private equity investment firm focused on assisting middle-market companies build value over the long term and was one of the founding members of Fresh Direct, LLC. Calise was also a consultant with the Industrial Products Group at PriceWaterhouse in its Chicago office.
Calise is the founder of the Associates, an organization within the New York Foundling Hospital that mentors and raises money for orphans and children at risk. Calise received a Bachelor of Arts in Economics from the University of Chicago, as well as certifications in insurance and finance.
President and CEO, Chitogenx
Phil Deschamps is an experienced and dedicated healthcare executive, and currently is the President and CEO of Chitogenix, formerly, Ortho Regenerative Technologies. Since his tenure at Chitogenix began in March of 2022, Deschamps’s primary mandate is to uncover expanded commercial uses for the company’s proprietary bio-polymer drug combination products.
During his career, Deschamps has worked with some of the most respected healthcare and pharmaceutical companies across the globe. He founded Helius Medical Technologies, took it public and raised $100M for product commercialization. Prior to the formation of Helius Medical Technologies, he was the President and CEO of GWS, a worldwide operation supporting the globalization of the Pharma sector and expanded GWS into 16 countries.
He also served in several marketing positions during his career and now often consults with clients regarding strategic business and marketing opportunities.
Dechamps graduated with a BSc from the University of Ottawa in Ottawa, Canada.
Associate Professor Vice Chair, Department of Neurosciences, Cleveland Clinic
Tara M. DeSilva, PhD, is an Associate Professor at the Cleveland Clinic and Case Western Reserve University School of Medicine. The focus of her work and that of the DeSilva laboratory is to understand neuroinflammatory processes that contribute to autoimmune and neurodegenerative diseases.
DeSilva’s work combines innovative brain imaging with single cell transcriptomics to understand neuro-immune interactions in both white and gray matter structures in the brain, which occurs during the development and disease. An extension of the studies has included the visual system with the utilization of retinal imaging as a biomarker for neurodegeneration in the brain.
She serves on many governmental and foundation scientific grant review panels, including the National Institutes of Health and the National Multiple Sclerosis Society. She is also known as an expert speaker and is actively involved with many international societies.
After receiving her PhD from the University of Pennsylvania, she completed her postdoctoral training at Children’s Hospital Boston, Harvard Medical School.
Founder and CEO, BluChip Solutions
As an accomplished and respected sales executive, with over three decades of experience, Chris Cochran founded BluChip Solutions, a provider of IT consulting and managed services solving complex business challenges. Cochran now uses his sales and business acumen in his role as CEO for BluChip.
Chris has achieved many accomplishments as CEO at BluChip. He has led a successful acquisition/buyout, secured a long-term partnership with one of the nation’s largest universities, and established a national sales model with a network of regional sales directors, account managers, and recruiters.
Bringing deep experience in sales and operations, his insight and quality of leadership added bench strength to both Mastech Digital and ASGN as the organizations went public. Chris has held executive sales and operational roles at global corporations. He served as EVP of Sales and Marketing at VELOCITY World Media, an experiential television network. Prior to that role, Cochran was a senior executive for over two decades with Mastech Digital, where he was the Senior Vice President of Global Sales and Operations. Additionally, Cochran was the Executive Director of Sales and Operations for ASGN, a leading provider of IT services. And earlier in his career, he functioned as a senior executive for Hewlett Packard Enterprises.
In addition to his sales and operational experience, Cochran also serves as the Director of the Christian Cochran Legacy Fund through the Pittsburgh Foundation. He has also served on the board of trustees for the Pine-Richland Opportunities Fund, a non-profit educational foundation providing staff grants and student scholarships.
Cochran received his Bachelor of Science degree in Public Administration and International Law from the University of Tennessee.
Chief of Neurosurgery, Emeritus, Holy Redeemer Hospital
Gene Salkind, M.D., is a well-known and respected neurosurgeon in the Philadelphia area. Practicing for over 35 years outside of Philadelphia, PA, he has been affiliated with a university practice of general neurological surgery since 1985, when he was selected as the Chief Resident in Neurosurgery at the Hospital of the University of Pennsylvania.
In addition to holding professorships at the University of Pennsylvania, the Allegheny Health Education and Research Foundation, and currently at the Lewis Katz School of Medicine, Dr. Salkind is known as expert writer and speaker. He has authored many peer reviewed journal articles and has given countless lectures on many topics related to neurosurgery.
Currently, Salkind sits on the board of directors for a variety of organizations, from biotechnology companies to drug delivery and digital corporations, as well as Bio Symetrics, a company developing automated pre-processing, integrated analytics, and predictive modeling to make machine learning accessible to scientists and providers.
Salkind graduated from the University of Pennsylvania in 1974 with a BA, cum laude, and received his medical degree for the Lewis Katz School of Medicine in 1979.
Corporate Headquarters 105 Bradford Road, Suite 420 Wexford, PA 15090 +1 (724) 934-6467 firstname.lastname@example.org
This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent official corporate documents on file with the U.S. Securities and Exchange Commission. The statements that are not historical facts contained in releases or in our posted events and presentations are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company’s Securities and Exchange Commission filings. Coeptis Therapeutics Holdings, Inc. does not undertake any obligation to update forward-looking statements after the date of such releases except to the extent required under applicable federal and state securities laws. This website contains links to websites maintained by other companies. Coeptis Therapeutics is providing these links to readers only as a convenience. The inclusion of any link does not imply that Coeptis Therapeutics endorses any third-party website or third-party company or product. Coeptis Therapeutics does not have any control over the content of such third-party websites and assumes no responsibility whatsoever for the functionality of such websites or for the accuracy of any information presented at such other websites.
© Copyright Coeptis 2023